Uso do infliximab na consulta de gastrenterologia pediátrica The use of infliximab in a pediatric gastroenterology consultation

Introdu o: O infliximab e um anticorpo monoclonal utilizado na doen a inflamatória intestinal (DII) refrataria. Objetivo: Avaliar a resposta clinica e os efeitos adversos da terapêutica com infliximab na DII em doentes pediátricos. Métodos: Estudo descritivo, analítico e transversal dos doentes da consulta de gastrenterologia pediátrica que ingressaram em protocolo terapêutico com infliximab. Resultados: Dos 6 doentes que realizam terapêutica monoclonal com infliximab, 5 apresentam doen a de Crohn moderada a grave e um colite ulcerosa. Verificou-se remiss o clinica em 5 doentes. Observou-se resolu o das altera es analíticas apos 6 meses de terapêutica. Verificaram-se 2 rea es alérgicas ligeiras e uma eleva o transitória das transaminases. Conclus es: Em concordancia com o descrito na literatura, na nossa popula o a terapeutica com infliximab tem sido bem tolerada e eficaz no controlo da doen a. Introduction: Infliximab is a monoclonal antibody used in refractory inflammatory bowel disease (IBD). Aim: To evaluate the clinical response and adverse effects of infliximab therapy in paediatric IBD patients. Methods: Analytic, descriptive and cross sectional study of Outpatient Clinic of Pediatric Gastroenterology treated with infliximab. Results: Of six patients treated with infliximab, five have moderate to severe Crohn’s disease and one present Ulcerative Colitis. There was clinical remission in five patients. Resolution in analytical changes was observed after 6 months of therapy. There were two mild allergic reactions and a transient elevation of transaminases. Conclusions: In accordance with the literature, in our population, infliximab therapy has been well tolerated and effective in disease control.